SuperworthRoivant Sciences ROIV
- Market cap
- $26.4B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- a loss over the last year
- Price to sales
- n/m
- a sliver of sales
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $7.5M
- −68% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −3.1%
Roivant Sciences' trailing earnings are negative, so it has no PE. Revenue was $7.5M over the last twelve months, down 68% on a year earlier.
Charts
Financials
| Income statement | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.6M−71% | $15.6M−9% | $28.9M+6% | $8M−63% | $4.5M+23% | $9M−42% | $7.6M−74% | $2.2M−73% | $1.6M−65% | $2M−78% | $2.5M−67% | $1.4M−34% | |
| R&D | $114.8M−13% | $108.1M−14% | $120.9M−8% | $120.5M−4% | $143.1M+25% | $141.6M+31% | $145.2M+20% | $152.9M+27% | $164.6M+15% | $165.4M+17% | $198.9M+37% | $202M+32% |
| SG&A | $88.6M−44% | $128.2M−24% | $169.6M+35% | $99.9M−36% | $202.9M+129% | $141.5M+10% | $147.1M−13% | $134M+34% | $143.1M−30% | $175.1M+24% | $158.3M+8% | $165.5M+24% |
| −$213.9M−24% | $5.1B | −$266M+14% | −$102.2M−63% | −$341.7M+60% | −$274.4M | −$285M+7% | −$284.9M+179% | −$306.2M−10% | −$339.2M+24% | $415.2M | −$366M+29% | |
| Interest expense | $9.2M+11% | $9.4M+12% | $7.2M−16% | $13.4M+50% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$241.4M−23% | $5.2B | −$191.5M+7% | −$19.6M−94% | −$224.4M−7% | −$234.5M | −$203.1M+6% | −$269.3M+1271% | −$159M−29% | −$290.4M+24% | $454.1M | −$294.6M+9% |
| $3.2M+50% | $22.4M+693% | −$5.8M+52% | $12M+583% | $12.5M+285% | −$25.6M | $49.3M | $4.6M−61% | $7M−44% | $23.3M | $98.4M+99% | −$4M | |
| Net income | −$304.3M+4% | $5.1B | −$151.1M+350% | $95.3M | −$230.2M−24% | $169.4M−97% | −$206.5M+37% | −$223.4M | −$113.5M−51% | −$265.9M | $303M | −$189.8M−15% |
| −$0.40−5% | $6.03 | −$0.19+280% | $0.12 | −$0.31−23% | $0.23−96% | −$0.29+53% | −$0.33 | −$0.17−45% | −$0.38 | $0.42 | −$0.26−21% | |
| 770.2M+10% | 844.5M+18% | 802.9M+8% | 781.6M+3% | 735.5M−5% | 722.7M−14% | 707.3M−12% | 680.3M−13% | 680.9M−7% | 696.9M−4% | 717.7M+2% | 720.8M+6% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY20 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q2 FY26 | $3.7M | $2.1M to $7.2M | −$0.37 | −$0.70 to −$0.08 | 2 |
| Q3 FY26 | $12.3M | $4.9M to $20.9M | −$0.37 | −$0.70 to −$0.08 | 2 |
| Q4 FY26 | $35.9M | $14.3M to $61M | −$0.35 | −$0.68 to −$0.08 | 1 |
| Q1 FY27 | $52.8M | $21M to $89.6M | −$0.33 | −$0.63 to −$0.07 | 1 |
| Q2 FY27 | $73.1M | $29M to $124.1M | −$0.31 | −$0.60 to −$0.07 | 1 |
| Q3 FY27 | $107.6M | $42.8M to $182.8M | −$0.29 | −$0.56 to −$0.06 | 1 |
| Q4 FY27 | $161.9M | $64.3M to $274.9M | −$0.24 | −$0.46 to −$0.05 | 1 |
Peers
Companies in Biotechnology nearest Roivant Sciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ROIVRoivant Sciences | $26.4B | n/m | 2.1× | n/m | n/m | −68% | n/m |
| UTHRUnited Therapeutics | $25.2B | 21.0× | 14.1× | 22.0× | 8.0× | +2% | 41.6% |
| INCYIncyte | $23.5B | 14.7× | 36.9× | 49.5× | 4.0× | +27% | 27.7% |
| ALNYAlnylam Pharmaceuticals | $30B | 37.8× | 69.2× | 26.7× | 6.2× | +95% | 16.8% |
| ONCBeOne Medicines | $42.9B | 67.6× | 68.4× | 48.1× | 7.0× | +34% | 10.7% |
| EXELExelixis | $16B | 20.3× | 22.8× | n/m | 6.6× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.5B | 20.9× | 42.8× | n/m | 4.3× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.3B | 37.5× | 21.3× | n/m | 8.6× | +41% | 24.9% |
| TECHBIO-TECHNE | $11.4B | 63.1× | 61.6× | n/m | 9.4× | −0% | 15.0% |
| RGENRepligen | $10B | 242× | 120× | n/m | 12.7× | +16% | 5.3% |
| KRYSKrystal Biotech | $9.2B | 39.0× | 42.7× | n/m | 20.9× | +23% | 54.8% |
| Peer median | $15.2B | 37.6× | 42.8× | 37.4× | 7.5× | +25% | 22.9% |
Investors who own it
Investors we follow who held Roivant Sciences at the end of Jun 30, 2026, from their 13F filings.
- David EinhornGreenlight Capital1.9% of portfolio
- Lee AinslieMaverick Capital0.9% of portfolioadded
- Andreas HalvorsenViking Global Investors0.6% of portfoliotrimmed
- Ron BaronBaron Capital0.0% of portfolio
- Polen CapitalPolen Capital0.0% of portfolionew
More on Roivant Sciences
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .